OncologyNew stomach cancer combination keeps nearly 40% alive at 3 years
Updated HERIZON-GEA-01 results at ESMO 2026 show zanidatamab regimens beat trastuzumab on survival in HER2-positive stomach and oesophageal cancer, though with a notable risk of diarrhoea.
23 October 2026